Aptevo Therapeutics (APVO) Given Daily News Impact Score of 0.18
Media stories about Aptevo Therapeutics (NASDAQ:APVO) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.5505371621276 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Analysts Anticipate Aptevo Therapeutics Inc (APVO) to Announce ($0.32) EPS (americanbankingnews.com)
- ETFs with exposure to Aptevo Therapeutics, Inc. : December 11, 2017 (finance.yahoo.com)
- Aptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples (finance.yahoo.com)
- Aptevo Therapeutics Inc. (APVO) VP Randy Joe Maddux Acquires 25,000 Shares (americanbankingnews.com)
Shares of Aptevo Therapeutics (APVO) opened at $3.98 on Friday. Aptevo Therapeutics has a 1-year low of $1.15 and a 1-year high of $4.50. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.67 and a current ratio of 7.76.
APVO has been the subject of several analyst reports. ValuEngine upgraded Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, October 12th. Piper Jaffray Companies restated an “overweight” rating and issued a $6.00 target price on shares of Aptevo Therapeutics in a research note on Thursday, October 5th.
In other Aptevo Therapeutics news, VP Randy Joe Maddux purchased 25,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were purchased at an average price of $2.76 per share, with a total value of $69,000.00. Following the acquisition, the vice president now directly owns 25,000 shares in the company, valued at approximately $69,000. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 15.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Aptevo Therapeutics (APVO) Given Daily News Impact Score of 0.18” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/aptevo-therapeutics-apvo-given-daily-news-impact-score-of-0-18/1765341.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.